Biocon fully integrates Biocon Biologics in US$5.5bil agreement


BENGALURU: Indian biopharmaceutical company Biocon says it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics businesses under one roof.

Biocon said it will acquire the remaining stakes in Biocon Biologics from Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through a share swap of 70.28 Biocon shares for every 100 Biocon Biologics shares, at a price of 405.78 rupees (US$4.51) per Biocon share.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

MPOB: Malaysian palm oil industry well-positioned for EUDR compliance
Is Malaysia's AI boom at risk?
SC unveils Sukuk PRISMA
99 Speed Mart cautiously optimistic on resilient demand for essentials
CIMB Islamic targets doubling of Islamic wealth assets by 2030
Big Caring Group posts RM72.52mil net profit ahead of Bursa listing
Citaglobal completes Perak hydropower acquisitions, strengthening power generation in its new energy business
TWL Holdings proposes RM26mil acquisition of Wisma TWL
Dialog remains focused on long-term strategies amid global uncertainties
Yes Group IPO public portion subscribed 2.80 times ahead of ACE Market debut

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read